Analysts, who are highly bullish on the stock, have fretted for some time that Viking needed a partner to actually make the product, assuming it gains regulatory approval. Viking ...
Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...
Viking Therapeutics, Inc. (VKTX) closed at $29.73 in the latest trading session, marking a +0.61% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 0.91% for the ...
Viking clears Q4 views, provides an update on cruise bookings. Shares ease as travel stocks fall on demand warnings. Viking Holdings shares dropped Tuesday as executives warned of macroeconomic ...
Viking has found a manufacturing partner ... Roche takes big step in weight-loss field with $5.3 billion deal. Novo Nordisk shares fall. -Ciara Linnane This content was created by MarketWatch ...